Results 31 to 40 of about 280,456 (250)

Low-density lipoprotein apheresis is associated with removal of SARS-CoV-2 antibodies. [PDF]

Ther Apher Dial, 2022
Low‐density lipoprotein apheresis is not specific to lipoproteins but removes immunoglobulins as well. It remains elusive, whether protective SARS‐CoV‐2 antibodies after vaccination from COVID‐19 are eliminated as well.
Bertram S, Pfab T, Albert C, Schmidt S, Passfall J, Haesner M, Seidel M, Hölzer B, Seibert FS, Doevelaar A, Rohn B, Zgoura P, Babel N, Westhoff TH.   +13 more
europepmc   +2 more sources

Lipoprotein Apheresis Acutely Reverses Coronary Microvascular Dysfunction in Patients With Severe Hypercholesterolemia. [PDF]

JACC Cardiovasc Imaging, 2019
Wu MD, Moccetti F, Brown E, Davidson BP, Atkinson T, Belcik JT, Giraud G, Duell PB, Fazio S, Tavori H, Tsimikas S, Lindner JR.   +11 more
europepmc   +3 more sources

Lipoprotein apheresis: an established therapeutic modality for homozygous familial hypercholesterolemia patients refractory to PCSK9 inhibitors: a case report and literature review. [PDF]

Thromb J
Guan M, Wang H, Wang F, Liang S, Ling L, Wang B, Zhang L.   +6 more
europepmc   +3 more sources

Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey. [PDF]

Orphanet J Rare Dis, 2021
Background Homozygous familial hypercholesterolemia (HoFH) is a rare life-threatening condition that represents a therapeutic challenge. The vast majority of HoFH patients fail to achieve LDL-C targets when treated with the standard protocol, which ...
D'Erasmo L, Gallo A, Cefalù AB, Di Costanzo A, Saheb S, Giammanco A, Averna M, Buonaiuto A, Iannuzzo G, Fortunato G, Puja A, Montalcini T, Pavanello C, Calabresi L, Vigna GB, Bucci M, Bonomo K, Nota F, Sampietro T, Sbrana F, Suppressa P, Sabbà C, Fimiani F, Cesaro A, Calabrò P, Palmisano S, D'Addato S, Pisciotta L, Bertolini S, Bittar R, Kalmykova O, Béliard S, Carrié A, Arca M, Bruckert E.   +34 more
europepmc   +2 more sources

Comparison of plasma separation using centrifugation or filtration for MONET lipoprotein apheresis in patients with cardiovascular disease and severe dyslipidemia. [PDF]

Ther Apher Dial, 2022
Homozygous or severe heterozygous familial hypercholesterolemia and elevated lipoprotein(a) levels may be treated with membrane filtration. The MONET system (Fresenius Medical Care, Bad Homburg, Germany) involves plasma separation by centrifugation or ...
Waitz G, Atiye S, Gauly A, Prophet H.
europepmc   +2 more sources

Lipoprotein Apheresis Alleviates Treatment-Resistant Peripheral Artery Disease Despite the Normal Range of Atherogenic Lipoproteins: The LETS-PAD Study. [PDF]

J Atheroscler Thromb
Aim: Peripheral artery disease (PAD) severely impairs patient prognosis and quality of life (QOL). Although lipoprotein apheresis (LA) has been applied to patients with PAD and elevated serum atherogenic lipoproteins, we hypothesized that LA can be ...
Ueda E, Ishiga K, Wakui H, Kawai Y, Kobayashi R, Kinguchi S, Kanaoka T, Saigusa Y, Mikami T, Yabuki Y, Goda M, Machida D, Fujita T, Haruhara K, Sugano T, Azushima K, Toya Y, Tamura K.   +17 more
europepmc   +2 more sources

Combined Treatment With Lipoprotein Apheresis and Hemodialysis in Patients With Severe Cardiovascular Disease, High Lipoprotein(a) and End Stage Renal Disease. [PDF]

J Clin Apher
Röseler T, Kayser D, Schlieper G, Bernhardt WM.   +3 more
europepmc   +3 more sources

Early low-density lipoprotein apheresis for steroid-resistant minimal change disease with acute kidney injury: a case report. [PDF]

CEN Case Rep
Hiramatsu M, Inoue M, Kamegai N, Michiya O, Yamamoto J.   +4 more
europepmc   +3 more sources

Switching from lipoprotein apheresis to evolocumab in FH siblings on hemodialysis: case reports and discussion. [PDF]

CEN Case Rep, 2021
Ishii T, Ogura M, Nakamori H, Hori M, Harada-Shiba M, Tamura K, Oyama K.   +6 more
europepmc   +2 more sources

Favorable therapeutic efficacy of low-density lipoprotein apheresis for nephrotic syndrome with impaired renal function. [PDF]

Ther Apher Dial, 2022
Many reports have shown the therapeutic efficacy of LDL apheresis (LDL‐A) in drug‐resistant nephrotic syndrome (NS) for improvement of heavy proteinuria and severely impaired renal function.
Muso E, Sakai S, Ogura Y, Yukawa S, Nishizawa Y, Yorioka N, Saito T, Mune M, Sugiyama S, Iino Y, Hirano T, Hattori M, Watanabe T, Yokoyama H, Sato H, Uchida S, Wada T, Shoji T, Oda H, Mori K, Kimura H, Ito O, Nishiyama A, Maruyama S, Inagi R, Fujimoto S, Tsukamoto T, Suzuki Y, Honda H, Babazono T, Tsuruya K, Yuzawa Y.   +31 more
europepmc   +2 more sources